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Background: Relatively little is known about how depression amongst people with chronic illness is identified and
managed in diverse primary health care settings. We evaluated the role of complex physical needs in influencing
current practice of depression screening, documentation and antidepressant prescriptions during a 12-month
period, among adults with Type 2 diabetes attending Aboriginal and Torres Strait Islander primary care health
centres in Australia.
Methods: We analysed clinical audit data from 44 health centres participating in a continuous quality improvement
initiative, using previously reported standard sampling and data extraction protocols. Eligible patients were those
with Type 2 diabetes with health centre attendance within the past 12 months. We compared current practice in
depression screening, documentation and antidepressant prescription between patients with different disease
severity and co-morbidity. We used random effects multiple logistic regression models to adjust for potential
confounders and for clustering by health centre.
Results: Among the 1174 patients with diabetes included, median time since diagnosis was 7 years, 19% of
patients had a co-existing diagnosis of Ischaemic Heart Disease and 1/3 had renal disease. Some 70% of patients
had HbAc1>7.0%; 65% had cholesterol >4.0 mmol1-1 and 64% had blood pressure>130/80 mmHg. Documentation
of screening for depression and of diagnosed depression were low overall (5% and 6% respectively) and lower for
patients with renal disease (Adjusted odds ratio [AOR] 0.21; 95% confidence interval [CI] 0.14 to 0.31 and AOR 0.34;
95% CI 0.15 to 0.75), and for those with poorly controlled disease (HbA1c>7.00 (AOR 0.40; 95% CI 0.23 to 0.68 and
AOR 0.51; 95% CI 0.30 to 84)). Screening for depression was lower for those on pharmaceutical treatment for
glycaemic control compared to those not on such treatment. Antidepressant prescription was not associated with
level of diabetes control or disease severity.
Conclusions: Background levels of depression screening and documentation were low overall and significantly
lower for patients with greater disease severity. Strategies to improve depression care for vulnerable populations are
urgently required. An important first step in the Australian Indigenous primary care context is to identify and
address barriers to the use of current clinical guidelines for depression screening and care.
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Clinically un-identified co-morbid depression amongst
people with diabetes has been recognised as a major
public health problem in a number of countries [1].
Screening for depression, and appropriate follow up and
management are recommended in numerous diabetes
and general practice guidelines worldwide, [2-5] and use
of formal depression screening tools for diabetes has
been incentivised for primary care in the UK Quality and
Outcomes Framework (QOF) since 2006 [6]. Depression
screening is also recommended in Australian General
Practice, for those at higher than average risk, including
Aboriginal and Torres Strait Islander middle-aged adults,
and people with chronic illness [4,5,7]. Relatively little is
known about the gap between evidence-based guidelines
and routine practice in different primary care settings
[8]. There is a particular dearth of information about
adherence to guidelines in provision of health care to
Aboriginal and Torres Strait Islander people, who have
the poorest health of any group in Australia.
A number of depression and mental health risk screening
tools have been developed for routine use and their
suitability for use with Indigenous Australians has been
assessed [9]. Psychometric properties of the PHQ-9,
PHQ-2+ have been well studied in clinical populations
generally; [10] amongst patients with diabetes; [11] and in
Aboriginal and Torres Strait Islander populations [11-13].
The psychological distress domain (K-5) - a modified
version of the Kessler Psychological Distress Scale-10
(K-10) has been used in survey settings in Australia
amongst Indigenous adults [14]. Whilst the Kessler tools
measure distress rather than depression, their scores
correlate well with depression (and anxiety). A 13-item
screening tool, including mental health risk, and alcohol
and drug related risk has been developed and validated
specifically for Indigenous populations [15]. Current
practice in relation to the use of these and other tools
amongst Aboriginal and Torres Strait Islander patients in
general, and those with chronic illness, is unknown.
It has been shown that in primary care settings patients
with more complex physical needs, such as multiple
co-morbidities, are less likely to have major depression
treated than those with more straightforward clinical
presentations [16]. A few studies have reported on adher-
ence to delivery of guideline-scheduled services for pre-
ventive and medical aspects of diabetes care in the context
of other competing demands [17,18]. To our knowledge,
no previous studies have explored the extent to which
competing physical demands, including poorly controlled
disease and disease severity, may be related to depression
identification and care for people with diabetes specifically.
This is an important issue because of the known asso-
ciations between untreated depression and poor self
management, poor cardio-metabolic control, and thedevelopment of diabetes-related complications [19-23] with
potential to perpetuate a negative downward spiral. It is also
a particularly important issue in respect of Aboriginal and
Torres Strait Islander populations, who are known to have
a disproportionate burden of both uncontrolled diabetes,
and poor mental health, including depression. Our paper
reports on a cross-sectional analytic study of clinical audit
data from patients with Type 2 diabetes receiving routine
care in Indigenous primary care centres in Australia. We
report on evidence-practice gaps, and compare differences
in depression screening, documentation and management
between patients with different levels of disease severity,
co-morbidity and diabetes control.
Methods
Study design and data source
We used clinical audit data from the Audit and Best-
practice for Chronic Disease Extension (ABCDE) project,
a national quality improvement initiative which aims to
improve quality of care in a range of priority aspects of
Indigenous primary health care in Australia, including
chronic illness care, preventive care, and maternal and
child health care [24].
While mainstream Australians access primary care
through a universal system of general practice funded
through Medicare, primary care systems for Indigenous
people are more complex, with three major services
sectors: Indigenous community controlled services, state
and territory funded/operated services, and general
practices. Indigenous community controlled services,
and state and territory funded/operated services, and
their service populations, are the setting for this project.
These services (“health centres”) are at the forefront of
providing primary health care, particularly in rural and
remote settings where there are few medical practitioners.
Health centres range in size from small centres (where in
some cases the regular staff consists of only a single nurse,
with other staff providing services through regular visits),
through to large health centres staffed by a range of health
professionals. What they have in common is the intention
to increase access to comprehensive primary health care
for Aboriginal and Torres Strait Islander populations. The
areas served by health centres participating in this study
were characterised by a high burden of chronic disease,
low health literacy and high levels of socio-economic
disadvantage.
Forty four health centres participating in the ABCDE
project were included, located in 4 States/Territories.
These were all the participating health centres that had
conducted clinical audits of patients with diagnosed type 2
diabetes between April and December 2009, and therefore
had all used an audit tool that included information on
depression screening. The majority of the health centres
(n=34/44) were located in rural or remote areas, 7 in
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areas. At each participating health centre, a random
sample of 30 records of clients aged 16 years or older with
a documented diagnosis of Type 2 diabetes was audited.
An additional criterion for inclusion was that the client
had to have lived in the community for a minimum of 6 of
the previous 12 months. For centres with 30 or fewer
clients with diabetes all records meeting the criteria were
audited. Based on this sampling approach, we obtained a
sample comprising 1174 adults (median age 51.5 years)
with a clinical diagnosis of type 2 diabetes (median time
since diagnosis 7 years). Some 36% of respondents were
identified as having renal disease, 19% had a record of
co-morbid ischaemic heart disease and 58% had a record
of hypertension.
Measures
Screened participants were those with a record of having
been screened for depression using a formal named
screening tool within the past 12 months. Standard
screening tools included the K-5, K-6, K-10, PHQ-2+,
PHQ-9 and Edinburgh Postnatal Depression Screening
tool (EPDS). Screening status and documentation of
depression, and other mental illness was extracted by
trained data extractors through examining the patients’
medical summary sheets, hospital discharge summaries
and other relevant summaries. Medication records
were reviewed for evidence of a current prescription of
antidepressant drugs.
For measures of cardio-metabolic control we extracted
from clinical records the most recently documented
values of Haemoglobin A1c (HbA1c), total cholesterol,
blood pressure and albumin/creatinine ratio (ACR) within
12 months prior to the audit. We presented these indicators
in a dichotomous format using cut-points for target levels
for reference categories. Cut-points were selected based
on diabetes clinical guidelines recommended for use in
Australian Indigenous populations at the time of the study
[25]. Documented diagnoses of renal disease, ischaemic
heart disease, hypertension, and hyperlipaemia were recor-
ded as present or absent, and treatment for diabetes was
recorded as no medication (reference category), oral
medications or insulin, with or without oral medications.
Other information extracted from clinical records
included sex, age, smoking status and BMI. Information
was also extracted on overall delivery of scheduled
services through 13 service items which the clinical
guidelines used across the states/territories recommend
for people with diabetes. We constructed an overall
measure of quality of clinical (medical) care through
summing the 13 items and dividing the sum of
services delivered by 13. The list of service items
included in this measure, and its prior use has been
previously reported [26].Statistical analysis
Means, proportions and medians were used to summarise
data as appropriate. Our data had inherent multilevel,
dependency structure, as data collected at the individual
patient level were clustered within health centres, which
in turn were clustered within jurisdictions. Multilevel
random effects logistic regression techniques were used to
explore various explanatory models of disease severity
for depression screening, documentation and current pre-
scription of antidepressants. Such models are suitable for
this purpose as they allow (and account for) the possibility
of residual correlation between individuals within groups.
Having been screened for depression using a formal
named tool; having a documented diagnosis of depression
in the clinical record; and having a current prescription of
antidepressant medication were treated as dependent
variables in the models. Collinearity amongst the inde-
pendent variables was explored prior to model fitting,
removing variables where collinearity was indicated. All
analyses were conducted using Stata software, version
10 (StataCorp, College Station, Tex, USA).Results
Variation in screening, documentation and management
of depression
Of the 44 health centres included in the study, 4
had used a named standard formal depression/distress
screening tool in the preceding year. Amongst those
health centres which had screened at least one client,
there was wide variation in proportion of clients scree-
ned, with the lowest health centre having screened
37% of their clients and the highest 67%. Across
all health centres, 5% of clients had been screened
(Table 1).
The most common screening tool used was a module of
5 questions from the Kessler Psychological Distress Scale
(“K-5”). K-5 scores ranged from 5 to 20 (mean=0.10.9,
SD=2.99). Using the accepted cut off of 12, 18% (n=10) of
those screened using this tool were classified as having
high levels of distress, consistent with depressive or an-
xiety disorders. Further exploration of the data revealed
that the majority of patients screened (69%) scored 11 or
higher.
Regardless of whether or not they had been screened,
6% (70 people) of patients across 24 health centres had a
documented diagnosis of depression, 5% had a diagnosis
of another mental illness and 6% of patients had a current
prescription of antidepressant medication. Documented
depression ranged from 0 to 33% between health centres.
Of the 65 people with a current prescription of anti-
depressant drugs, 39% (n=25) did not have a documented
diagnosis of depression, nor documentation of any other
mental illness.
Table 1 Variation in screening, documentation and management of depression by participating centres and jurisdictions




Total sample 1174 44
Screened for depression with named formal tool 55 4 5.0 0 to 52.3 0 to 66.6
Documented diagnosis of depression 70 24 6.0 2.5 to 24.8 0 to 33.3
Documented diagnosis of other mental illness 55 26 4.7 2.4 to 11.0 0 to 33.0
Current prescription of antidepressant drugs 65 28 5.5 2.8 to 19.3 0 to 33.0
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depression documented and medication-treated groups
From Table 2, depression screening and documentation
were significantly higher for those overweight, compared
to those not overweight. Overall, 49% of the sample with
recorded BMI were in the overweight category (BMI>24)
and 27% of the sample had a BMI of over 30 (obese).
Participants aged 35–50 years were more likely to have
been screened for depression than those 15–35 years.
There was no significant difference in prescription of anti-
depressants or depression documentation by age group.
Clients with a formal diagnosis of renal disease were
less likely to have been screened for depression and less
likely to have documented depression than those without
renal disease. We also expanded the definition of renal
disease/impairment to include patients with a recorded
ACR>3.4. Using this expanded definition, those with renal
disease/impairment (60% of patients with an ACR value
documented) were also less likely to have been screened for
depression than those without renal disease/impairment.
People treated with oral hypoglycaemics had significantly
lower levels of screening compared to those not on oral
medications.
There was no relation between other co-morbid condi-
tions and depression screening, documentation or current
antidepressant prescription. Patients with a diagnosis of
hyperlipidaemia were more likely to have been screened
for depression, to have documented depression, and to
have a current prescription of antidepressant medication
than those without hyperlipidaemia. However this associ-
ation was found to be mediated by BMI and did not retain
significance in the multivariate model, which included
adjustment for BMI, and other factors (Table 3).
Clinical targets for diabetes management
Approximately 70% of the sample with complete clinical
records (n=1003) had HbA1c higher than the recom-
mended 7.0% level; 65% had cholesterol higher than the
recommended 4.0 mmol1-1 level and 64% had blood
pressure higher than the recommended 130/80 mmHg
(Table 2). Those with HbA1c at higher than recommended
levels were significantly less likely to have been screened
for depression using a standard tool, and also significantly
less likely to have documented depression than those withtarget HbA1c levels (Tables 2 and 3). We also checked
for relationships between depression indicators and level
of abnormal reading for each of the clinical indicators
(not shown). Using a higher cut-off (>=5.5 mmolL-1) to
define high total blood cholesterol, we found that those
with high cholesterol were significantly less likely to
have been screened for depression using formal tools
(OR=0.39; 95% CI=0.21; 0.74) compared to those with
target levels of cholesterol.
Table 3 shows that after adjustment for overall quality
of care and relevant demographic factors, patients with
renal disease, and those with higher than target levels of
HbA1c remained significantly less likely to be screened
for depression or have documented depression than patients
without these conditions. Similarly, patients treated
with oral medications and/or insulin were less likely to
have been screened for depression than those not on
pharmaceutical treatment for glycaemic control.
Discussion
We found low overall use of formal depression screening
tools, low levels of documentation of depression, and
prescription of antidepressant medications.
After adjustment for potential confounders, patients
with more severe diabetes-related disease were less than
half as likely to have been screened for depression using
a formal tool. Those with documented renal disease and
those with HbA1c above target levels, were less than one
third and less than one half as likely to have been screened
for depression and to have documented depression
respectively.
Our finding of lack of attention to depression overall,
and a disproportionate lack amongst patients with
competing demands for management of physical illness, is
largely consistent with previous reports. Two US-based
studies found that about 45%-51% of diabetes patients
with depression were undiagnosed, [1,27] and that undiag-
nosed depression was more common amongst those with
co-morbid cardiovascular disease (Prevalence Ratio [PR],
1.5; 95% CI: 1.2-1.9), and those in poor or fair health. (PR,
2.8; 95% CI: 2.1-3.6) [1]. Neither of these studies included
an analysis of depression recognition gaps in relation
to levels of cardio-metabolic control. One recent
single-practice study that examined depression screening
Table 2 Characteristics of the sample by depression screening, documentation and prescription of antidepressant medication
Variables Total sample Screened with standard named tool Documented depression Prescription of antidepressant medication
n % n % OR 95% CI n % OR 95% CI n % OR* 95% CI
Total 1174 100 57 5.0 70 6.0 65 5.5
Sex
Male 489 41.7 22 4.5 Reference 25 5.1 Reference 25 5.1 Reference
Female 685 58.3 35 5.1 1.14 0.69 1.89 45 6.6 1.31 0.73 2.34 40 5.8 1.15 0.57 2.32
Age group
15-35 years 111 9.5 2 1.8 Reference 4 3.6 Reference 4 3.6 Reference
35-49 years 434 37.0 20 4.6 2.63* 1.51 4.60 35 8.1 2.35 0.84 6.58 24 5.5 1.57 0.56 4.37
50-64 years 450 38.3 16 3.6 2.01 0.69 5.89 24 5.3 1.51 0.51 4.49 28 6.2 1.77 0.62 5.08
65+ years 179 15.2 19 10.6 6.47 1.26 33.27 7 3.9 1.09 0.35 3.40 9 5 1.42 0.45 4.44
Smoking status
Non-smoker 769 65.5 32 4.2 Reference 40 5.2 Reference 39 5.1 Reference
Current smoker 405 34.5 25 6.2 1.52 0.62 3.72 30 7.4 1.48 0.89 2.46 26 6.4 1.28 0.83 1.99
BMI
BMI 24 or less 572 50.9 5 0.9 Reference 19 3.3 Reference 23 4 Reference
BMI>24 551 49.1 52 9.4 11.82** 3.58 39.02 47 8.5 2.71* 1.35 5.46 39 7.1 1.82 0.87 3.80
Ischaemic heart disease
No 951 81.0 41 4.3 Reference 55 5.8 Reference 49 5.2 Reference
Yes 223 19.0 16 7.2 1.72 0.71 4.14 15 6.7 1.17 0.7 2.10 16 7.2 1.42 0.72 2.82
Renal disease
No 742 63.2 48 6.5 Reference 58 7.8 Reference 47 6.3 Reference
Yes 432 36.8 9 2.1 0.31** 0.17 0.56 12 2.8 0.34** 0.2 0.75 18 4.2 0.64 0.33 1.26
ACR level
<=3.4 270 33.8 28 10.4 Reference 17 6.3 Reference 17 6.3 Reference
>3.4 528 66.2 11 2.8 0.18** 0.09 0.37 29 5.5 0.87 0.4 1.8 22 4.2 0.65 0.3 1.23
Hypertension
No 491 41.8 19 3.9 Reference 24 4.9 Reference 20 4.1 Reference
Yes 683 58.2 38 5.6 1.46 0.75 2.87 46 6.7 1.41 0.8 2.34 45 6.6 1.66 0.96 2.88
Hyperlipidaemia†
No 629 53.6 19 3.0 Reference 29 4.6 Reference 96 26 Reference




















Table 2 Characteristics of the sample by depression screening, documentation and prescription of antidepressant medication (Continued)
Diabetes treatment
No medication 150 14.3 14 8.3 Reference 11 6.5 Reference 11 6.5 Reference
Oral 678 63.8 29 3.9 0.44* 0.26 0.76 40 5.3 0.81 0.40 1.62 40 5.3 0.80 0.42 1.50
Insulin 222 21.9 14 5.4 0.63 0.38 1.04 19 7.4 1.14 0.50 2.58 19 7.4 1.26 0.53 3.01
HbA1c level
<=7.00% 301 30.0 28 9.3 Reference 27 9 Reference 19 6.3 Reference
>7.00%* 702 70.0 25 3.6 0.36** 0.23 0.55 36 5.1 0.55* 0.34 0.88 35 5 0.78 0.46 1.31
Total cholesterol
<=4.00 mmol1-1 323 34.9 21 6.5 Reference 20 6.2 Reference 10 3.1 Reference
>4.00 mmol 1-1 603 65.1 30 5 0.75 0.46 1.24 40 6.6 1.08 0.72 1.61 39 6.5 2.16 0.99 4.73
Blood pressure
<=130/80 mmHg 404 36.4 19 4.7 Reference 25 6.2 Reference 22 5.4 Reference
>130/80 mmHg 706 63.6 37 5.2 1.12 0.63 1.98 41 5.8 0.93 0.66 1.33 37 5.2 0.96 0.54 1.70
*P<0.01; **P<0.001
Significance tests adjusted for clustering by health centre. Sample size might vary with missing data. BMI, body mass index.
† Further analysis (not shown in the table) revealed that the association between hyperlipidaemia and depression & screening was mediated by BMI; after adjusting for this interaction, no substantial effect of




















Table 3 Adjusted effects of select disease severity indicators on depression screening, documentation and
antidepressant prescription†
Variables Screened with formal tool Documented Depression Prescription of antidepressant drugs
AOR 95% CI AOR 95% CI AOR 95% CI
Renal disease
No Reference Reference Reference
Yes 0.21** 0.14 0.31 0.34** 0.15 0.75 0.69 0.37 1.29
ACR level
<=3.4 Reference Reference Reference
>3.4 0.16** 0.08 0.32 0.77 0.38 1.51 0.50 0.23 1.03
Diabetes treatment
No medication Reference Reference Reference
Oral 0.37** 0.23 0.61 0.80 0.38 1.69 0.99 0.49 2.02
Insulin/insulin+oral 0.48** 0.30 0.78 1.13 0.45 2.83 1.61 0.59 4.33
HbA1c level
<=7.00% Reference Reference Reference
>7.00%* 0.40** 0.23 0.68 0.51** 0.30 0.84 0.80 0.48 1.33
Total cholesterol
<=4.00 mmol1-1 Reference Reference Reference
>4.00 mmol 1-1 0.83 0.48 1.44 1.00 0.67 1.51 2.05 0.89 4.72
Hyperlipidaemia†
No Reference Reference Reference
Yes 1.86 0.85 4.09 1.23 0.47 3.22 1.28 0.61 2.69
†adjusted for sex, age, BMI and overall delivery of scheduled services; only those disease severity indicators significant in the bi-variate analysis are included
*P<0.01; **P<0.001.
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lower than anticipated use of formal tools, even within an
incentivised system, and limited detection of new cases as
a result of screening [28].
The lack of attention to depression overall in our study
population, and lower levels for patients with worse
physical health, may explain in part the poor achievement
of clinical targets for diabetes management in our study
population. The low rates of screening reported in our
study raise questions about the utility and acceptability of
available depression screening tools for Aboriginal and
Torres Strait Islander patients. Amongst those screened,
lower than expected case finding raises questions about
what is currently being done about mental health care in
routine primary health practice. It also raises questions
about the circumstances under which routine screening
for depression is likely to be most effective. Our finding
that those overweight were more likely to be screened for
depression than those not overweight, further suggests
that clinicians may be informally triaging patients prior to
screening. Various determinants of the utility of depression
screening tools, including the intentions of providers in
selecting whom to screen and why [29] need to be
addressed in the context of providing comprehensiveprimary health care for Aboriginal and Torres Strait
Islander people.
A previous study has demonstrated that the extent to
which competing demands of physical illness influence
attention paid to emotional and social well being is likely
to be influenced by the type of depression treatment
that is available, and whether or not this treatment is
acceptable to patients [30]. These authors found that
competing demands were a factor in determining care
for depression, but only for patients for whom the
depression care offered was acceptable. The implication is
that improving depression care, including for Aboriginal
and Torres Strait Islander patients, requires that models
of care are culturally acceptable and flexible enough to
respond to individual preferences, and that access to
acceptable care is equitably available - including to those
with complex physical needs. In our study, the finding that
people with poorer cardio-metabolic control or disease
severity were generally no more or less likely to have
prescriptions of antidepressants, may similarly reflect
some degree of non-acceptability of antidepressant
treatment amongst some patients, or their providers.
Racial disparities in antidepressant treatment of depressive
symptoms in people with diabetes have been previously
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suggesting that such differences are likely to reflect
differential treatment by health professionals, and/or
cultural differences in acceptance of medical help for
emotional distress. Some have suggested greater access to
psychological interventions of proven efficacy is urgently
needed. These may be of greater benefit than drug
treatment, particularly for patients with chronic illness,
where concerns over drug interactions can preclude use
of antidepressant drugs. Higher levels of depression,
distress and socio-political contributions to depression
amongst Aboriginal and Torres Strait Islander peoples
present additional considerations for the development
of appropriate models of care in this setting [32]. There
are few available guidelines to assist primary care providers
in selecting the most appropriate interventions for this
vulnerable population in general, or specifically for those
with diabetes. Brief social interventions focusing on
problem solving and awareness, such as those contained in
the model developed through the Australian Integrated
Mental Health initiative (AIMhi) in the Northern Territory,
have shown promise in reducing distress measured
with the K-10, and in improving other mental wellbeing
outcomes using a number of different measures, [33] but
such approaches have not been widely adopted.
The main limitations of our study are, first, health
centres participated voluntarily in the study and were
all enrolled in a continuous quality improvement inter-
vention for chronic illness care. Therefore the data are
not necessarily representative for the States/Territories
involved, and may overestimate or underestimate attention
to depression care. Also, the focus of our study is on
depression care for people with Type 2 diabetes, and the
findings may not be generalisable to patients with other
chronic conditions. Second, we relied on clinical medical
records to obtain data. Documented care may not be an
accurate reflection of actual care. Third, our sampling
approach, based on unweighted sex- and age-stratified
samples, was designed to facilitate analysis of quality of
care between communities, not to produce population
estimates. Nonetheless our sampling approach is suitable
for exploring the strength and direction of associations,
reported as the main finding of this paper. Fourth, we did
not have information on any non-drug treatment for
depression that may have been made available to these
patients. This may mean that we underestimated attention
paid by primary care providers to emotional and social
wellbeing. Fifth, the cross-sectional nature of our study
limited our ability to disentangle potential relationships
between depression screening, and having a diagnosis of
depression. For example, if those with depression had
greater disease severity, and were also less likely to have
been screened, reported associations between disease
severity and screening may have been due to confounding.On the other hand, if those with depression had greater dis-
ease severity, and were more likely to have been screened
(consistent with a usual care pathway) the reported associa-
tions between depression screening and disease severity
would be underestimated. Finally, owing to the nature of
the data and the limited numbers of health centres using
formal depression screening tools, we were unable to
explore the impact of health centre and systems factors,
which are likely to be additional important determinants of
mental health care received in the primary care context.
Conclusion
We found that patients with poorer cardio-metabolic
control and greater disease severity were less likely to have
attention paid to potential co-morbid depression. This
finding may have relevance to other settings of high
service load, and is a cause for concern given the increasing
burden of non-communicable diseases worldwide, and
the known disproportionate high risk of mental distress
amongst people with chronic illness, including diabetes.
Improving depression identification and care for vulnerable
high risk populations is likely to require a range of
strategies. These may include strategies to raise awareness
of evidence-practice gaps in this area; to develop and
implement optimal delivery systems for identification and
management of depression; and to ensure that depression
care is acceptable and flexible enough to accommodate
individual and community preferences. An important first
step in the Aboriginal and Torres Strait Islander primary
care context will be to identify and address barriers to the
use of current clinical guidelines regarding depression
identification and management including for the most
vulnerable populations with complex physical needs.
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